BioLineRx

BLRX

ATLANTA, GA – – (ACCESSWIRE – January 5, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against BioLineRx Ltd.  (“BioLineRx” or the “Company”) (NASDAQ: BLRX).  The lawsuit alleges BioLineRx made materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including: (1) the Company was not well enough financed to develop its drug candidate, Motixafortide, while at the same time advancing other pipeline programs; and (2) BioLineRx would require a loan from Kreos Capital VII Aggregator SCSP in an aggregate principal amount of up to $40 million and then also would require a $15M securities offering to facilitate the commercial launch of Motixafortide.

If you bought shares of BioLineRx between February 23, 2021 and September 19, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/biolinerx/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 6, 2023.

Registration Deadline

Lead Plaintiff Deadline Has Passed

March 6, 2023

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.